DISCOVERY OF ANTI-HCV AND NS5B RDRP INHIBITION ACTIVITIES OF NOVEL ANTHRAQUINONES BY IN VITRO AND IN-SILICO APPROACH

A confirmed target for drug development, the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase(RdRP) is a crucial and unique part of the HCV RNA replication machinery. We describe the identification ofcompounds with anti-HCV and NS5B RdRp inhibitory activity in this research investigation. Here, we investigatedthe activity of anthraquinone compounds using both an in vitro and an in silico method. These substances were discovered to be active with strong anti-HCV and NS5B RdRp inhibitory properties. Our findings also suggest thatanthraquinones may be optimized and that novel anthraquinone derivatives with enhanced cell and enzyme-basedactivity may produced.Keywords: RNA-dependent RNA polymerase, anthraquinones, molecular docking, hepatitis C virus, and NS5Binhibitors